Clinical effects of clarithromycin on persistent inflammation following Haemophilus influenzae-positive acute otitis media. (April 2014)

• Record Type: Journal Article
• Authors: Iino, Yukiko; Yoshida, Naohiro; Kato, Toshinori; Kakizaki, Keiko; Miyazawa, Tetsuo; Kakuta, Hiroyuki
• Is Part Of: Acta oto-laryngologica. Volume 135:Number 3(2015)
• Page Start: 217
• Page End: 225
• Publication Date: 2014-04
• Subjects: Biofilm -- cell invasion -- clinical effects; Otolaryngology -- Periodicals; Ear -- Diseases -- Periodicals; Throat -- Diseases -- Periodicals; Otolaryngology -- Electronic Resources; Otorhinolaryngologic Diseases; 617.8
• DOI: 10.3109/00016489.2014.975893
• Languages: English
• ISSNs: 0001-6489

Abstract

Abstract: Conclusion: Additional treatment with clarithromycin (CAM) reduced persistent middle ear inflammation after acute otitis media (AOM) caused by Haemophilus influenzae in children. CAM is a treatment option for persistent inflammation following AOM and to prevent continuing otitis media with effusion. Objective: We conducted a clinical study to evaluate a new method of treatment for persistent inflammation after AOM in children. Methods: H. influenzae-infected children with AOM were treated acutely with antimicrobial agents, after which those still demonstrating effusion of the middle ear cavity received additional treatment with carbocysteine (S-CMC) alone or S-CMC combined with clarithromycin (CAM) for 1 week. The two regimens were compared in terms of clinical effects. Results: After the initial acute treatment, many patients still showed abnormal otoscopic findings. At the completion of additional treatment, there were no significant differences between the two treatment groups. However, 1 week after completion of additional treatment, the prevalence of a diminished light reflex was significantly lower in the CAM + S-CMC group than in the S-CMC group ( p = 0.017). The prevalence of redness of the tympanic membrane also tended to be lower in the combined treatment group than in those receiving a single drug ( p = 0.097).